Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Linezolid
Drug ID BADD_D01295
Description Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci.[L32965] Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class.[A233425] A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Indications and Usage For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.
Marketing Status Prescription; Discontinued
ATC Code J01XX08
DrugBank ID DB00601
KEGG ID D00947
MeSH ID D000069349
PubChem ID 441401
TTD Drug ID D07UYO
NDC Product Code 62332-183; 66794-219; 0904-6553; 0009-5137; 59762-1308; 68382-413; 67457-324; 66499-0047; 63323-713; 55111-947; 46708-936; 0781-3431; 0409-4883; 0009-5140; 63629-8576; 73377-115; 65841-166; 60687-309; 57664-683; 66022-0103; 70518-1226; 68578-0009; 66022-0201; 31722-749; 59762-1307; 73309-004; 59285-021; 66794-236; 65427-821; 0054-0319; 65162-777; 46708-861; 72606-001; 70771-1111; 40032-022; 46708-183; 62512-0032; 66022-0206; 0009-4992; 58623-0129; 66298-7131; 55150-242; 66298-5137; 0009-5157; 58032-2009; 67457-843; 66039-825; 66298-5140; 57664-682; 66298-7807; 52562-019; 67877-419; 0009-5138; 0781-3433; 0009-7807; 68724-5135; 25021-169; 0009-5136
Synonyms Linezolid | N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide | Linezolide | Zyvox | U 100766 | 100766, U | PNU-100766 | PNU 100766 | PNU100766 | U-100766 | U100766
Chemical Information
Molecular Formula C16H20FN3O4
CAS Registry Number 165800-03-3
SMILES CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bone marrow failure01.03.03.0050.226404%
Cytopenia01.03.03.0120.007547%Not Available
Treatment failure08.06.01.0170.013781%Not Available
Hypertransaminasaemia09.01.02.0050.037734%Not Available
Acute kidney injury20.01.03.0160.116975%
Langerhans' cell histiocytosis15.09.03.008; 01.13.04.003; 22.01.01.016; 16.21.04.0030.030187%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.007547%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.018867%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.060374%Not Available
Candida infection11.03.03.0210.002953%
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.011320%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.008859%
Liver function test increased13.03.01.0440.015094%Not Available
CNS ventriculitis17.06.01.002; 11.01.03.0100.003937%Not Available
Full blood count abnormal13.01.07.0030.007547%Not Available
Full blood count decreased13.01.07.004--Not Available
Kussmaul respiration22.02.01.008; 14.01.01.0040.018867%Not Available
Nosocomial infection11.07.02.0060.002953%Not Available
Toxic optic neuropathy17.04.05.009; 12.03.01.033; 06.02.08.0030.083015%Not Available
Muscle abscess15.05.01.006; 11.01.17.0070.007547%Not Available
Clostridium difficile infection11.02.02.0090.001969%Not Available
Wound infection staphylococcal12.02.05.051; 11.02.05.0140.011320%Not Available
Renal salt-wasting syndrome20.05.03.021; 14.05.01.0110.015094%Not Available
Procalcitonin increased13.09.01.0260.007547%Not Available
Acute lung injury22.01.03.0100.003937%Not Available
Enterococcus test positive13.08.01.0080.018867%Not Available
Infective pulmonary exacerbation of cystic fibrosis22.03.01.023; 11.01.09.0160.011320%Not Available
The 13th Page    First    Pre   13    Total 13 Pages